The global human growth hormone market size was valued at USD 6.81 billion in 2024 and is projected to reach from USD 7.63 billion in 2025 to USD 18.75 billion by 2033, growing at a CAGR of 11.90% ...

OPKO Health’s weekly growth hormone injection could be approvable in adults without need for further clinical trials, the company has told pharmaphorum. The biotech has worked with Pfizer to co ...

In December 2014, Pfizer and OPKO began an agreement to develop hGH-CTP for growth hormone deficiency in adults and children, and for children who are small for gestational age and fail to show ...

For instance, in October 2021, Pfizer, Inc. and OPKO Health, Inc. updated their Biologics License Application to the U.S. FDA for the investigational drug somatropin to treat growth hormone ...

For instance, in October 2021, Pfizer, Inc. and OPKO Health, Inc. updated their Biologics License Application to the U.S. FDA for the investigational drug somatropin to treat growth hormone ...

Additionally, Pfizer’s strategic focus on obesity treatments, despite cautious expectations for danuglipron, remains a significant growth area. The company’s robust acquisitions strategy ...

Further, Pfizer's Q3 adjusted diluted EPS of $1.06 beat street estimates by 45 cents reflecting the translation of top-line growth into bottom-line gains larger than expected. This performance was ...

With over two decades in breast cancer research and patient support, Pfizer believes ... especially for patients with hormone receptor-positive (HR +)/human epidermal growth factor receptor ...

Despite normal hormone levels in her blood tests ... 4 No formal studies have established a link between breast parenchymal growth and the Pfizer COVID-19 vaccine. Although these social media ...

Pfizer said Tuesday. The company also cited sales growth from several other drugs, as total revenue climbed 31% to $17.7 billion in the recently completed quarter. Adjusted earnings totaled $1.06 ...